CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
November 2019—Qiagen launched its QIAseq Expanded Carrier Screening Panel, which provides identification of targets, genes, and other regions of interest responsible for more than 200 disease indications. The QIAseq panel is integrated with the company’s CLC Genomics Workbench and Clinical Insight (QCI)-Interpret for QIAseq to provide evidence-based, actionable insights. It leverages QIAseq’s single primer extension technology with unique molecular indices to enable the analytically sensitive identification of all types of variants critical to the study of inherited disorders.
In a separate release, the company announced an agreement with McKesson Medical-Surgical in which McKesson will serve as the exclusive distributor of the QIAstat-Dx syndromic testing solution in the acute market segment of U.S. hospitals with 200 beds or less and in other select segments. The agreement also makes McKesson a nonexclusive distributor for future expansion of QIAstat-Dx in nonacute retail clinics located in U.S. retail pharmacies. The agreement comes after the QIAstat-Dx and multiplex QIAstat-Dx Respiratory Panel received FDA 510(k) clearance in May.